[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351484-105":59,"doc-detail-351484-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-e3-ubiquitin-ligase-rnf180-modulates-the-egfrpi3kakt-pathway-to-reduce-cisplatin-resistance-in-non-small-cell-lung-cancer","The E3 ubiquitin ligase RNF180 modulates the EGFR/PI3K/AKT pathway to reduce cisplatin resistance in non-small cell lung cancer","","Non-small cell lung cancer remains highly lethal, and cisplatin resistance limits effective chemotherapy. The study investigates how the E3 ubiquitin ligase RNF180 influences cisplatin resistance, using RNF180-modified A549/DDP cells, in vitro assays, nude mouse xenograft models, and bioinformatics. RNF180 overexpression suppresses proliferation, migration, invasion, EMT, and drug-resistance proteins while promoting apoptosis. PLK2 is identified as a downstream substrate; PLK2 knockdown modifies malignant traits and cisplatin sensitivity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-e3-ubiquitin-ligase-rnf180-modulates-the-egfrpi3kakt-pathway-to-reduce-cisplatin-resistance-in-non-small-cell-lung-cancer/351484/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-e3-ubiquitin-ligase-rnf180-modulates-the-egfrpi3kakt-pathway-to-reduce-cisplatin-resistance-in-non-small-cell-lung-cancer/351484.png","ImageObject",300,407,{"name":92,"@type":93},"Angel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is cisplatin resistance a major problem in non-small cell lung cancer?","Question",{"text":112,"@type":113},"Cisplatin resistance significantly undermines first-line chemotherapy effectiveness in advanced non-small cell lung cancer, leading to poor outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What experimental strategies were used to test RNF180 in this study?",{"text":117,"@type":113},"A549/DDP cells were transduced with lentiviral vectors to adjust RNF180 expression, followed by in vitro assays, nude mouse xenograft models, and bioinformatics analyses.",{"name":119,"@type":110,"acceptedAnswer":120},"How does RNF180 reduce cisplatin resistance mechanistically?",{"text":121,"@type":113},"RNF180 suppresses the EGFR/PI3K/AKT signaling pathway and regulates its substrate PLK2, which together attenuate tumor chemoresistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351484,1790152976,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe E3 ubiquitin ligase RNF180 modulates the EGFR/PI3K/AKT pathway to reduce cisplatin resistance in non-small cell lung cancer  \nXiaoyan Song1,4, Wen Jiang1,4, Hongxuan Wei2, Yan Zhu2, Junmei Shu1􀀍, Chuandong Zhu1􀀍 & Fangfang Chen2,3􀀍  \nNon-small cell lung cancer (NSCLC) is recognized as one of the most aggressive cancers, and resistance to cisplatin significantly hinders effective clinical treatment. The role of the E3 ubiquitin ligase RNF180 in cisplatin resistance in NSCLC remains unclear. A549/DDP cells were transduced with lentiviral vectors to adjust RNF180 expression. In vitro experiments, nude mouse xenograft models, and bioinformatics analyses were used to verify the functions of RNF180 and its substrate, PLK2 . Quantitative real-time PCR (qRT-PCR) and Western blotting were used to detect the signaling pathways. RNF180 expression was significantly lower inA549/DDP cells than inA549 cells. Overexpression of RNF180 inhibited proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and drug resistance protein expression, while promoting apoptosis in vitro and in vivo. Meanwhile, the bioinformatics database identified PLK2 as a downstream substrate of RNF180, with PLK2 overexpressed inA549/  \nDDP cells. In vitro knockdown of PLK2 promoted the malignant phenotype and enhanced cisplatin resistance of A549/DDP cells. Besides, our results suggested that RNF180 inhibits NSCLC progression and attenuates cisplatin resistance by suppressing the EGFR/PI3K/AKT signaling pathway and regulating the activity of its substrate, PLK2. This study confirms that RNF180 inhibits NSCLC progression and attenuates tumor chemoresistance, and further elucidates its regulatory signaling pathways.  \nKeywords Non-small cell lung cancer, Cisplatin resistance, E3 ubiquitin ligase RNF180, EGFR/PI3K/AKT  \nGlobally, lung cancer continues to be the primary cause of mortality associated with cancer, especially in people aged 50 years and older1. Non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of lung cancer cases. Yet, its five-year survival rate is grim, falling below 20%, primarily because of frequent diagnoses at advanced stages2. This unfavorable outcome is directly related to inherent drug resistance3. In a clinical context, only a limited number of NSCLC patients are diagnosed at early stages (I/II), which can be addressed through surgical intervention. Conversely, more than 60% of patients are identified at locally advanced or metastatic stages (III/IV), indicating the need for standard chemoradiotherapy. Although cisplatin-based combination chemotherapy is the established first-line treatment for advanced NSCLC, the effectiveness of this approach is significantly compromised by chemoresistance4. Cisplatin (CDDP) mainly induces cytotoxicity by forming DNA adducts, which activate the DNA damage response and lead to apoptosis. Nevertheless, severe drug resistance critically undermines clinical results5. The mechanisms underlying resistance encompass a range of processes, including diminished drug uptake, increased efflux, altered drug metabolism, target mutations, enhanced DNA repair capacity, decreased mismatch repair efficiency, and evasion of apoptosis6. Therefore, a thorough exploration of the mechanisms driving cisplatin resistance is critical.  \n1Department of Oncology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing 210003, Jiangsu, China. 2Institute of Laboratory Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, Jiangsu, China. 3The First School of Clinical Medicine, Southern Medical University, Guangzhou, China. 4Xiaoyan Song and Wen Jiang contributed equally to this work. 􀀍 email:  \n[13675178344@163.com](13675178344@163.com); [zhucd@njucm.edu.cn](zhucd@njucm.edu.cn); [longysh@163.com](longysh@163.com)  \n[www. nature.com/scie","cbCaioZbmwnAeRbs","https://ap.wps.com/l/cbCaioZbmwnAeRbs","pdf",3392895,13,"English","# Background and rationale\n## Clinical burden of non-small cell lung cancer\n## Cisplatin resistance mechanisms\n# Study focus and experimental approach\n## RNF180 in ubiquitin–proteasome signaling\n## EGFR/PI3K/AKT pathway context\n# Results summary\n## RNF180 alters malignant behavior and drug resistance\n## PLK2 acts as a downstream substrate\n# Conclusions","[{\"question\":\"Why is cisplatin resistance a major problem in non-small cell lung cancer?\",\"answer\":\"Cisplatin resistance significantly undermines first-line chemotherapy effectiveness in advanced non-small cell lung cancer, leading to poor outcomes.\"},{\"question\":\"What experimental strategies were used to test RNF180 in this study?\",\"answer\":\"A549/DDP cells were transduced with lentiviral vectors to adjust RNF180 expression, followed by in vitro assays, nude mouse xenograft models, and bioinformatics analyses.\"},{\"question\":\"How does RNF180 reduce cisplatin resistance mechanistically?\",\"answer\":\"RNF180 suppresses the EGFR/PI3K/AKT signaling pathway and regulates its substrate PLK2, which together attenuate tumor chemoresistance.\"}]","The E3 ubiquitin ligase RNF180 modulates the EGFR/PI3K/AKT pathway to reduce cisplatin resistance in non-small cell lung cancer | PDF",1790094368,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73428eeda9a59dc61a94d6462d84d1c2.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6edccd14fe1c02140e71e3395199e983.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d9091dbbeebb2cdab9bd74115e4eb86.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9ecc76a3f12d88c8bfd3486c695e625.webp",980,1287]